5-Lipoxygenase and Leukotriene B(4) Receptor Are Expressed in Human Pancreatic Cancers but Not in Pancreatic Ducts in Normal Tissue

Overview

Journal Am J Pathol

Publisher Elsevier

Specialty Pathology

Date 2002 Aug 7

PMID 12163367

Citations 58

Authors

Rene Hennig

Xian-Zhong Ding

Wei-Gang Tong

Matthias B Schneider

Jens Standop

Helmut Friess

Markus W Buchler

Parviz M Pour

Thomas E Adrian

Affiliations

Soon will be listed here.

Abstract

The 5-lipoxygenase (5-LOX) pathway is critical for pancreatic cancer cell growth and escape from apoptosis. Inhibition of 5-LOX blocks proliferation and induces apoptosis in human pancreatic cancer cells. However, the expression of 5-LOX and its downstream signaling pathway have not been investigated in human pancreatic adenocarcinoma. Reverse transcriptase-polymerase chain reaction revealed expression of 5-LOX mRNA in all pancreatic cancer cell lines tested including, PANC-1, AsPC-1, and MiaPaCa2 cells, but not in normal pancreatic ductal cells. The expression of 5-LOX protein in pancreatic cancer cell lines was demonstrated by Western blotting. Finally, 5-LOX up-regulation in human pancreatic cancer tissues was verified by intense positive staining in cancer cells by immunohistochemistry. Staining for the 5-LOX protein was particularly evident in the ductal components of the more differentiated tumors but not in ductal cells in normal pancreatic tissues from cadaver donors. Immunohistochemistry also revealed strong staining of cancer tissues with an antibody to the receptor of the downstream 5-LOX metabolite, leukotriene B(4). The current study demonstrated marked expression of 5-LOX and the leukotriene B(4) receptor in human pancreatic cancer tissues. These findings provide further evidence of up-regulation of this pathway in pancreatic cancer and that LOX inhibitors are likely to be valuable in the treatment of this dreadful disease.

Citing Articles

Alpha-Lipoic Acid-Mediated Inhibition of LTB Synthesis Suppresses Epithelial-Mesenchymal Transition, Modulating Functional and Tumorigenic Capacities in Non-Small Cell Lung Cancer A549 Cells.

Torres M, Rios J, Valle A, Indo S, Gv K, Lopez-Moncada F Curr Ther Res Clin Exp. 2025; 102():100765.

PMID: 39816494 PMC: 11731977. DOI: 10.1016/j.curtheres.2024.100765.

MK591 (Quiflapon), a 5-lipoxygenase inhibitor, kills pancreatic cancer cells via downregulation of protein kinase C-epsilon.

Monga J, Ghosh R, Guddeti R, Chitale D, Khan G, Ghosh J Front Oncol. 2024; 14:1387535.

PMID: 38746674 PMC: 11091401. DOI: 10.3389/fonc.2024.1387535.

Lipoxygenases at the Intersection of Infection and Carcinogenesis.

Amoah A, Pestov N, Korneenko T, Prokhorenko I, Kurakin G, Barlev N Int J Mol Sci. 2024; 25(7).

PMID: 38612771 PMC: 11011848. DOI: 10.3390/ijms25073961.

The role of human 5-Lipoxygenase (5-LO) in carcinogenesis - a question of canonical and non-canonical functions.

Kahnt A, Hafner A, Steinhilber D Oncogene. 2024; 43(18):1319-1327.

PMID: 38575760 PMC: 11065698. DOI: 10.1038/s41388-024-03016-1.

ALOX5 acts as a key role in regulating the immune microenvironment in intrahepatic cholangiocarcinoma, recruiting tumor-associated macrophages through PI3K pathway.

Chen J, Tang Y, Qin D, Yu X, Tong H, Tang C J Transl Med. 2023; 21(1):923.

PMID: 38124204 PMC: 10734103. DOI: 10.1186/s12967-023-04804-1.

References

Peters-Golden M, Brock T . Intracellular compartmentalization of leukotriene synthesis: unexpected nuclear secrets. FEBS Lett. 2001; 487(3):323-6. DOI: 10.1016/s0014-5793(00)02374-7. View

Charleson S, Prasit P, Leger S, Gillard J, Vickers P, Mancini J . Characterization of a 5-lipoxygenase-activating protein binding assay: correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition. Mol Pharmacol. 1992; 41(5):873-9. View

Ghosh J, Myers C . Central role of arachidonate 5-lipoxygenase in the regulation of cell growth and apoptosis in human prostate cancer cells. Adv Exp Med Biol. 2000; 469:577-82. DOI: 10.1007/978-1-4615-4793-8_84. View

Yeo C, Cameron J . Improving results of pancreaticoduodenectomy for pancreatic cancer. World J Surg. 1999; 23(9):907-12. DOI: 10.1007/s002689900598. View

Mancini J, Li C, Vickers P . 5-Lipoxygenase activity in the human pancreas. J Lipid Mediat. 1993; 8(3):145-50. View

Pour P . The role of Langerhans islets in pancreatic ductal adenocarcinoma. Front Biosci. 1997; 2:d271-82. DOI: 10.2741/a190. View

Molina M, Lemoine M, Frazier M, Sinicrope F . Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 1999; 59(17):4356-62. View

Ulrich A, Schmied B, Matsuzaki H, Moyer M, Ricordi C, Adrian T . Establishment of human pancreatic ductal cells in a long-term culture. Pancreas. 2000; 21(4):358-68. DOI: 10.1097/00006676-200011000-00006. View

Balcarek J, Theisen T, Cook M, Varrichio A, Hwang S, Strohsacker M . Isolation and characterization of a cDNA clone encoding rat 5-lipoxygenase. J Biol Chem. 1988; 263(27):13937-41. View

10.

Hruban R, Wilentz R, Kern S . Genetic progression in the pancreatic ducts. Am J Pathol. 2000; 156(6):1821-5. PMC: 1850064. DOI: 10.1016/S0002-9440(10)65054-7. View

11.

Rose . Dietary Fat, Fatty Acids and Breast Cancer. Breast Cancer. 1997; 4(1):7-16. DOI: 10.1007/BF02967049. View

12.

Permert J, Herrington M, Kazakoff K, Pour P, Adrian T . Early changes in islet hormone secretion in the hamster pancreatic cancer model. Teratog Carcinog Mutagen. 2001; 21(1):59-67. View

13.

Dixon R, Diehl R, Opas E, Rands E, Vickers P, Evans J . Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature. 1990; 343(6255):282-4. DOI: 10.1038/343282a0. View

14.

Nathan M, Pek S . Lipoxygenase-generated icosanoids inhibit glucose-induced insulin release from rat islets. Prostaglandins Leukot Essent Fatty Acids. 1990; 40(1):21-5. DOI: 10.1016/0952-3278(90)90111-w. View

15.

Funk C . Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001; 294(5548):1871-5. DOI: 10.1126/science.294.5548.1871. View

16.

Funk C, Matsumoto T, Hoshiko S, Radmark O, Samuelsson B . Characterization of the human 5-lipoxygenase gene. Adv Prostaglandin Thromboxane Leukot Res. 1989; 19:470-3. View

17.

Woutersen R, Appel M . Modulation of pancreatic carcinogenesis by antioxidants. Food Chem Toxicol. 1999; 37(9-10):981-4. DOI: 10.1016/s0278-6915(99)00093-9. View

18.

Avis I, Jett M, Boyle T, Vos M, Moody T, Treston A . Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest. 1996; 97(3):806-13. PMC: 507119. DOI: 10.1172/JCI118480. View

19.

Hong S, Avis I, Vos M, Martinez A, Treston A, Mulshine J . Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res. 1999; 59(9):2223-8. View

20.

Shannon V, Ramanadham S, Turk J, Holtzman M . Selective expression of an arachidonate 12-lipoxygenase by pancreatic islet beta-cells. Am J Physiol. 1992; 263(5 Pt 1):E828-36. DOI: 10.1152/ajpendo.1992.263.5.E828. View